Literature DB >> 12594281

Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.

Peck S Tan1, Amanda L Gavin, Nadine Barnes, Duane W Sears, David Vremec, Ken Shortman, Sebastian Amigorena, Patricia L Mottram, P Mark Hogarth.   

Abstract

The mouse Fc gamma RI is one of the most fundamentally important FcRs. It participates in different stages of immunity, being a low affinity receptor for T-independent IgG3 and yet a high affinity receptor for IgG2a, the product of a Th1 immune response. However, analysis of this receptor has been difficult due largely to the failure to generate specific Abs to this FcR. We have made use of the polymorphic differences between BALB/c and NOD/Lt mice to generate mAb specific for the Fc gamma RI of BALB/c and the majority of in-bred mouse strains. Three different mAb were obtained that detected Fc gamma RI encoded by the more common Fcgr1(a) and Fcgr1(b) alleles, and although they identified different epitopes, none inhibited the binding of IgG to Fc gamma RI. When bound to Fc gamma RI, these mAb induced calcium mobilization upon cross-linking. Several novel observations were made of the cellular distribution of Fc gamma RI. Resting and IFN-gamma-induced macrophages expressed Fc gamma RI as well as mast cell lines. Both bone marrow-derived and freshly isolated dendritic cells from spleen and lymph nodes expressed Fc gamma RI. A class of DC, uniquely found in s.c. lymph nodes, expressed the highest level of Fc gamma RI and also high levels of MHC class II, DEC205, CD40, and CD86, with a low level of CD8 alpha, corresponding to the phenotype for Langerhans-derived DC, which are highly active in Ag processing. Thus, in addition to any role in effector functions, Fc gamma RI on APC may act as a link between innate and adaptive immunities by binding and mediating the uptake of T-independent immune complexes for presentation, thereby assisting in the development of T-dependent immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594281     DOI: 10.4049/jimmunol.170.5.2549

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  IgG subclasses determine pathways of anaphylaxis in mice.

Authors:  Héloïse Beutier; Caitlin M Gillis; Bruno Iannascoli; Ophélie Godon; Patrick England; Riccardo Sibilano; Laurent L Reber; Stephen J Galli; Mark S Cragg; Nico Van Rooijen; David A Mancardi; Pierre Bruhns; Friederike Jönsson
Journal:  J Allergy Clin Immunol       Date:  2016-04-26       Impact factor: 10.793

2.  A canine model of cutaneous late-phase reactions: prednisolone inhibition of cellular and cytokine responses.

Authors:  Cherie M Pucheu-Haston; Dale Shuster; Thierry Olivry; Philippe Brianceau; Patrick Lockwood; Terrill McClanahan; Rene de Waal Malefyt; Jeanine D Mattson; Bruce Hammerberg
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

3.  Flow cytometric gating for spleen monocyte and DC subsets: differences in autoimmune NOD mice and with acute inflammation.

Authors:  Matthew B Dong; M Jubayer Rahman; Kristin V Tarbell
Journal:  J Immunol Methods       Date:  2015-09-05       Impact factor: 2.303

4.  Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.

Authors:  Caitlin E Mullarkey; Mark J Bailey; Diana A Golubeva; Gene S Tan; Raffael Nachbagauer; Wenqian He; Kyle E Novakowski; Dawn M Bowdish; Matthew S Miller; Peter Palese
Journal:  mBio       Date:  2016-10-04       Impact factor: 7.867

5.  Human IgG1 antibodies suppress angiogenesis in a target-independent manner.

Authors:  Sasha Bogdanovich; Younghee Kim; Takeshi Mizutani; Reo Yasuma; Laura Tudisco; Valeria Cicatiello; Ana Bastos-Carvalho; Nagaraj Kerur; Yoshio Hirano; Judit Z Baffi; Valeria Tarallo; Shengjian Li; Tetsuhiro Yasuma; Parthasarathy Arpitha; Benjamin J Fowler; Charles B Wright; Ivana Apicella; Adelaide Greco; Arturo Brunetti; Menotti Ruvo; Annamaria Sandomenico; Miho Nozaki; Ryo Ijima; Hiroki Kaneko; Yuichiro Ogura; Hiroko Terasaki; Balamurali K Ambati; Jeanette Hw Leusen; Wallace Y Langdon; Michael R Clark; Kathryn L Armour; Pierre Bruhns; J Sjef Verbeek; Bradley D Gelfand; Sandro De Falco; Jayakrishna Ambati
Journal:  Signal Transduct Target Ther       Date:  2016-01-28

6.  DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo.

Authors:  Christian H K Lehmann; Anna Baranska; Gordon F Heidkamp; Lukas Heger; Kirsten Neubert; Jennifer J Lühr; Alana Hoffmann; Katharina C Reimer; Christin Brückner; Simone Beck; Michaela Seeling; Melissa Kießling; Didier Soulat; Anne B Krug; Jeffrey V Ravetch; Jeanette H W Leusen; Falk Nimmerjahn; Diana Dudziak
Journal:  J Exp Med       Date:  2017-04-07       Impact factor: 14.307

7.  Mast cells and company.

Authors:  Friederike Jönsson; Marc Daëron
Journal:  Front Immunol       Date:  2012-02-20       Impact factor: 7.561

8.  Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation.

Authors:  Hozefa S Bandukwala; Bryan S Clay; Jiankun Tong; Purvi D Mody; Judy L Cannon; Rebecca A Shilling; J Sjef Verbeek; Joel V Weinstock; Julian Solway; Anne I Sperling
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307

9.  Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes.

Authors:  Melissa W Boulé; Courtney Broughton; Fabienne Mackay; Shizuo Akira; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Exp Med       Date:  2004-06-14       Impact factor: 14.307

10.  Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.

Authors:  David Llewellyn; Simone C de Cassan; Andrew R Williams; Alexander D Douglas; Emily K Forbes; Jaime R Adame-Gallegos; Jianguo Shi; Richard J Pleass; Simon J Draper
Journal:  J Leukoc Biol       Date:  2013-10-25       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.